Price T Rowe Associates Inc Fibrogen Inc Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Fibrogen Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 92,900 shares of FGEN stock, worth $28,799. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,900
Previous 117,258
20.77%
Holding current value
$28,799
Previous $276,000
69.93%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding FGEN
# of Institutions
111Shares Held
58MCall Options Held
2.14MPut Options Held
907K-
Primecap Management CO Pasadena, CA13.7MShares$4.23 Million0.01% of portfolio
-
Armistice Capital, LLC New York, NY8.94MShares$2.77 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$1.82 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.36MShares$1.04 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.41MShares$746,9910.0% of portfolio
About FIBROGEN INC
- Ticker FGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,741,200
- Market Cap $29.1M
- Description
- FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...